知镜 Cognispect · 医学文献与研究工作台

A phase II, randomised, placebo-controlled, double-blind trial of cannabis extract for amyotrophic lateral sclerosis: the EMERALD trial.

Urbi B, Sabet A, Hughes I, Bedlack R, Russo E, Broadley SA.
BMJ neurology open · 2026-11-11 · PMID 43022354

文献摘要

Introduction Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited disease-modifying treatment options. Preclinical and clinical data suggest that cannabinoid-based therapies may exert neuroprotective and symptomatic benefits. We conducted a trial to evaluate the effects of cannabis-based medicine extract (CBME) on disease progression in patients with ALS. Methods This was a randomised, double-blind, placebo-controlled trial. Participants received CBME or placebo for 6 months. The primary outcome was the difference in ALS Functional Rating Scale-Revised (ALSFRS-R) scores at the end of treatment (EOT). Secondary outcomes included adverse events, forced vital capacity (FVC), pain and spasticity measures, weight loss, cognition and quality of life. Results Due to COVID-19 restrictions and driving limitations, only 17 participants were enrolled (CBME: n=8; placebo: n=9), and 8 completed treatment (4 per group). At EOT, adjusted mean ALSFRS-R scores were 31.67 for CBME and 34.33 for placebo (difference: -2.66; 95% CI -7.25 to 1.92; p=0.18; n=8). No significant differences were observed in secondary outcomes. Post hoc analyses suggested potential effects of CBME on pain and cognition for further confirmation: usual pain intensity decreased by 2.52 points (95% CI -8.92 to 3.87, p=0.34; n=8), a decrease of 3 days in the number of pain days (95% CI -28.90 to 22.59, p=0.75; n=8), executive function improved by 7.71 points (95% CI 0.90 to 14.52; p=0.04; n=8) and a 5.68-point improvement in memory (95% CI -0.29 to 11.64; p=0.06; n=8). Conclusion This trial did not achieve the target sample size therefore was underpowered to demonstrate efficacy of cannabis in slowing ALS progression. However, exploratory analyses generated hypotheses regarding possible effects on pain and cognition which require confirmation in adequately powered studies. Trial registration number (ID: NCT03690791) on 27 September 2018.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。